…
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Manhattan Scients (MHTX) is an OTC‑Pink quoted microcap that, based on limited public disclosures, appears to be a development‑stage company focused on commercializing intellectual property in technology and life sciences. Long‑term growth may depend on successful commercialization or licensing of IP, strategic partnerships and regulatory approvals that could support revenue, which may appeal to investors seeking early‑stage IP exposure.
Material risks include limited public disclosure, low liquidity and thin trading, likely lack of revenues, high execution and financing risk such as dilution, and potential regulatory or legal exposure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -1.17M | -2.73M | -3.64M | 4.31M | -1.22M |
| Net income | -1.17M | -4.76M | -3.67M | 4.31M | -1.23M |
| Selling general administrative | 0.69M | 0.72M | 0.73M | 0.71M | 1.11M |
| Selling and marketing expenses | 0.00M | - | - | - | - |
| Gross profit | -0.00M | 0.05M | 0.05M | 0.05M | 0.10M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | -1.17M | -0.68M | -0.69M | -0.68M | -1.02M |
| Ebitda | -1.16M | -0.68M | -0.69M | -0.67M | -1.02M |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Non operating income net other | - | - | - | 5.01M | -0.19M |
| Operating income | -0.70M | -0.68M | -0.69M | -0.68M | -1.02M |
| Other operating expenses | 0.70M | 0.73M | 0.74M | 0.72M | 1.12M |
| Interest expense | 0.00M | 0.02M | 0.03M | 0.03M | 0.01M |
| Tax provision | - | - | - | - | 0.00M |
| Net interest income | 0.00M | -0.02M | -0.03M | -0.03M | -0.01M |
| Income tax expense | -1.17M | 2.03M | 0.03M | 0.03M | 0.01M |
| Total revenue | 0.00M | 0.05M | 0.05M | 0.05M | 0.10M |
| Total operating expenses | 0.70M | 0.73M | 0.74M | 0.72M | 1.12M |
| Cost of revenue | 0.00M | - | - | 0.72M | 0.00M |
| Total other income expense net | -0.46M | -2.05M | -2.95M | 4.99M | -0.20M |
| Net income from continuing ops | -1.17M | -2.73M | -3.64M | 4.31M | -1.22M |
| Net income applicable to common shares | - | - | -3.64M | 4.31M | -1.22M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 0.32M | 1.03M | 3.45M | 6.85M | 2.23M |
| Other current assets | 0.00M | 0.01M | 0.32M | 0.31M | 0.31M |
| Total liab | 2.12M | 2.73M | 2.42M | 2.17M | 3.23M |
| Total stockholder equity | -1.80M | -1.70M | 1.03M | 4.67M | -1.00M |
| Other current liab | 1.92M | 1.44M | 1.13M | 0.85M | 1.86M |
| Common stock | 0.56M | 0.56M | 0.56M | 0.56M | 0.56M |
| Capital stock | 0.56M | 0.56M | 0.56M | 0.56M | 0.56M |
| Retained earnings | -72.42M | -71.25M | -68.52M | -64.88M | -69.19M |
| Other assets | - | - | 0.00M | 0.30M | 0.60M |
| Cash | 0.07M | 0.17M | 0.23M | 0.35M | 0.26M |
| Total current liabilities | 2.12M | 1.67M | 1.36M | 1.01M | 2.09M |
| Current deferred revenue | 0.01M | - | - | - | - |
| Net debt | -0.01M | -0.07M | -0.10M | -0.25M | -0.18M |
| Short term debt | 0.06M | 0.11M | 0.13M | - | - |
| Short long term debt | 0.06M | 0.11M | 0.13M | - | - |
| Short long term debt total | 0.06M | 0.11M | 0.13M | 0.10M | 0.08M |
| Other stockholder equity | 69.56M | 69.00M | 69.00M | 69.00M | 67.63M |
| Property plant equipment | - | - | 0.00M | 0.01M | 0.00M |
| Total current assets | 0.07M | 0.19M | 0.55M | 0.67M | 0.57M |
| Long term investments | 0.24M | 0.84M | 2.90M | 5.88M | 1.04M |
| Net tangible assets | - | - | 1.03M | 4.67M | -1.00M |
| Short term investments | - | - | - | 5.88M | - |
| Net receivables | - | - | 0.30M | 0.30M | 0.30M |
| Long term debt | - | - | - | 0.10M | 0.08M |
| Inventory | - | - | -0.30M | -0.30M | -0.30M |
| Accounts payable | 0.13M | 0.12M | 0.10M | 0.16M | 0.23M |
| Accumulated other comprehensive income | -0.56M | - | - | - | - |
| Common stock total equity | - | - | - | 0.56M | 0.56M |
| Preferred stock total equity | - | - | - | 1.06M | - |
| Retained earnings total equity | - | - | - | -64.88M | -69.19M |
| Non currrent assets other | 0.00M | 0.00M | 0.00M | 0.30M | 0.60M |
| Non current assets total | 0.25M | 0.84M | 2.91M | 6.18M | 1.65M |
| Long term debt total | - | - | - | - | 0.08M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.10M | 0.33M | 0.30M | 0.18M | 0.04M |
| Change to liabilities | - | - | 0.17M | -0.01M | 0.34M |
| Total cashflows from investing activities | 0.10M | - | 0.30M | 0.48M | 0.34M |
| Net borrowings | -0.02M | - | - | - | 0.15M |
| Total cash from financing activities | -0.02M | -0.04M | - | 0.02M | 0.15M |
| Change to operating activities | - | - | -0.00M | 0.27M | -0.00M |
| Net income | -1.17M | -2.73M | -3.64M | 4.31M | -1.22M |
| Change in cash | -0.11M | -0.06M | -0.12M | 0.09M | 0.17M |
| Begin period cash flow | 0.17M | 0.23M | 0.35M | 0.26M | 0.09M |
| End period cash flow | 0.07M | 0.17M | 0.23M | 0.35M | 0.26M |
| Total cash from operating activities | -0.19M | -0.35M | -0.42M | -0.39M | -0.32M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | - | - | 0.30M | 0.30M |
| Other cashflows from financing activities | -0.02M | 0.33M | 0.30M | -0.02M | -0.21M |
| Change to netincome | - | - | 3.02M | 0.02M | 0.19M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash flows other operating | - | - | - | -4.74M | 0.36M |
| Cash and cash equivalents changes | - | - | - | 0.09M | 0.17M |
| Change in working capital | 0.51M | 0.33M | 0.17M | 0.26M | 0.34M |
| Other non cash items | 0.46M | 2.05M | 3.05M | -4.96M | 0.56M |
| Free cash flow | -0.19M | -0.35M | -0.42M | -0.39M | -0.32M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MHTX Manhattan Scients |
- -% |
0.00 | - | - | 78.30 | 15.64 | 281.64 | -1.61 |
| ABT Abbott Laboratories |
-0.10 0.10% |
103.87 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
- -% |
100.61 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.13 0.04% |
313.08 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.64 1.35% |
48.14 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Marvin Maslow | Founder & Chairman | 1938 |
| Mr. Emmanuel Tsoupanarias | Pres, CEO & Director | 1953 |
| Mr. Leonard C. Friedman | Sec. | 1938 |
| Mr. Robert Romeo Proulx | Pres of Imagion | 1958 |
| Mr. Marvin Maslow | Founder & Chairman of the Board | 1938 |
| Mr. Emmanuel Tsoupanarias | President, CEO & Director | 1953 |
| Mr. Leonard C. Friedman | Secretary | 1938 |
| Mr. Robert Romeo Proulx | President of Imagion | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.